IFT22

Across TCGA pan-cancer cohorts, IFT22 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IFT22 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IFT22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFT22 expression acts as an unfavorable survival marker.

DLBC are the cancer types where IFT22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

IFT22–DLBC (OS)

Open the DLBC breakdown →